shelf registration in the first quarter of
2008, there is a lack of comparability in the per share amounts
between the 2008 and 2007 periods presented.
CADENCE PHARMACEUTICALS, INC.
(a development stage company)
CONDENSED BALANCE SHEETS
September 30, December 31,
2008 2007
(unaudited)
Assets
Current assets:
Cash and cash equivalents $61,062,863 $55,392,921
Restricted cash 2,195,696 1,981,848
Prepaid expenses 337,450 751,046
Other current assets 126,615 208,275
Total current assets 63,722,624 58,334,090
Property and equipment, net 5,930,562 5,139,538
Restricted cash 537,586 885,434
Other assets 153,880 252,963
Total assets $70,344,652 $64,612,025
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $4,203,333 $1,974,991
Accrued liabilities 10,362,610 13,901,770
Current portion of long-term debt 8,320,222 5,617,928
Total current liabilities 22,886,165 21,494,689
Deferred rent 1,027,823 1,224,869
Long-term debt, less current portion
and discount 7,516,133 13,412,349
Other long-term liabilities
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1.
Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule2.
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update3.
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 20084.
Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline5.
Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)6.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML7.
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia8.
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients9.
WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO10.
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)11.
Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India